Physician profile
Jennifer Ann Gardner
NPI 1679982805
$8,805.58
in general payments reported to CMS, 2019-2025
34 companies · $3,177 in 2025
The $3,177 reported for 2025 was more than what 99% of Registered Nurse providers received nationally (typical 2025 total: $73.55).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $544 · 2022: $1,057 · 2023: $1,866 · 2024: $2,161 · 2025: $3,177.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,185 · Education: $19.57.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,185.12 |
| Education | $19.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,238.80 | 2021-2025 | |
| Janssen Biotech, INC. | $873.67 | 2022-2025 | Stelara, Tremfya |
| Takeda Pharmaceuticals U.S.A., INC. | $797.22 | 2021-2025 | Entyvio, Eohilia, Gattex |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $668.37 | 2021-2025 | Xifaxan, Trulance, Plenvu |
| Regeneron Healthcare Solutions, INC. | $620.64 | 2022-2025 | Dupixent |
| Ardelyx, INC. | $512.24 | 2023-2025 | Ibsrela |
| Pfizer INC. | $442.62 | 2021-2025 | |
| Genzyme Corporation | $426.78 | 2023-2025 | |
| Madrigal Pharmaceuticals | $337.42 | 2024-2025 | Rezdiffra, Resmetirom |
| Qol Medical, LLC | $247.38 | 2023-2025 | Sucraid |
| Phathom Pharmaceuticals, INC. | $246.15 | 2024-2025 | Voquezna |
| Celgene Corporation | $157.03 | 2021-2024 | Zeposia |
| Celltrion USA INC. | $138.17 | 2024-2025 | Vegzelma, Zymfentra |
| Intercept Pharmaceuticals, INC. | $122.93 | 2021-2024 | Ocaliva |
| Lilly USA, LLC | $115.63 | 2023-2025 | Omvoh |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $98.18 | 2021-2024 | Dificid |
| Vivus LLC | $89.74 | 2022-2025 | Pancreaze, Qsymia |
| Daiichi Sankyo INC. | $76.37 | 2021-2023 | Injectafer |
| Organon LLC | $64.23 | 2021-2025 | Hadlima, Renflexis |
| Ironwood Pharmaceuticals, INC | $60.12 | 2022-2024 | Linzess |
| Mallinckrodt Hospital Products INC. | $59.70 | 2025 | Terlivaz |
| Nestle Healthcare Nutrition INC. | $53.11 | 2021-2022 | |
| Ipsen Biopharmaceuticals, INC | $49.57 | 2024-2025 | Iqirvo |
| Gilead Sciences, INC. | $49.16 | 2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $42.02 | 2023 | |
| Exact Sciences Corporation | $35.26 | 2023-2024 | Cologuard Collection Kit |
| Boston Scientific Corporation | $32.62 | 2025 | Axonics |
| Medtronic, INC. | $30.93 | 2024 | Interstim |
| Orphalan INC | $28.92 | 2025 | Cuvrior |
| Aimmune Therapeutics, INC. | $23.85 | 2023 | |
| Novo Nordisk INC | $19.53 | 2025 | Wegovy |
| Intra-Sana Laboratories | $16.44 | 2021 | |
| Alexion Pharmaceuticals, INC. | $15.61 | 2021 | |
| Evoke Pharma, INC. | $15.17 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jennifer Gardner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.